Antihypertensive Effects of IGTGIPGIW Peptide Purified from Hippocampus abdominalis: p-eNOS and p-AKT Stimulation in EA.hy926 Cells and Lowering of Blood Pressure in SHR Model

Mar Drugs. 2022 May 26;20(6):354. doi: 10.3390/md20060354.

Abstract

The aim of this study was to assess the potential hypertensive effects of the IGTGIPGIW peptide purified from Hippocampus abdominalis alcalase hydrolysate (HA) for application in the functional food industry. We investigated the antihypertensive effects of IGTGIPGIW in vitro by assessing nitric oxide production in EA.hy926 endothelial cells, which is a major factor affecting vasorelaxation. The potential vasorelaxation effect was evaluated using 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate, a fluorescent stain. IGTGIPGIW significantly increased the expression of endothelial-derived relaxing factors, including endothelial nitric oxide synthase and protein kinase B, in EA.hy926 cells. Furthermore, oral administration of IGTGIPGIW significantly lowered the systolic blood pressure (183.60 ± 1.34 mmHg) and rapidly recovered the diastolic blood pressure (143.50 ± 5.55 mmHg) in the spontaneously hypertensive rat model in vivo. Our results demonstrate the antihypertensive activity of the IGTGIPGIW peptide purified from H. abdominalis and indicate its suitability for application in the functional food industry.

Keywords: EA.hy926; Hippocampus abdominalis; antihypertensive activity; peptide.

MeSH terms

  • Animals
  • Antihypertensive Agents* / pharmacology
  • Blood Pressure
  • Endothelial Cells
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III* / metabolism
  • Peptides / pharmacology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Inbred SHR
  • Smegmamorpha*

Substances

  • Antihypertensive Agents
  • Peptides
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Proto-Oncogene Proteins c-akt